Dr. Benjamin Michael Heyman, MD

Dr. Heyman practices at City of Hope National Medical Cente - City of Hope Lennar Oncology/Infusion - HOPD in Irvine, California.

Dr. Heyman's NPI, 1982995809, was assigned on April 26, 2011. Dr. Heyman graduated from UVA School of Medicine in 2011. Dr. Heyman holds California license A157684.

Dr. Heyman's primary practice is City of Hope National Medical Cente - City of Hope Lennar Oncology/Infusion - HOPD, at 1000 Fivepoint, Irvine, CA 92618.

Dr. Heyman's primary practice is City of Hope National Medical Cente - City of Hope Lennar Oncology/Infusion - HOPD in Irvine, California. Dr. Heyman is also affiliated with Hillcrest Medical Center. The medical group on file is City of Hope. Dmand AI also links Dr. Heyman to 1 more group practice or clinic, 1 other site and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Heyman practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Heyman's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Heyman is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Heyman's licenses on file in 2 states: California and North Carolina.

Dmand AI lists chronic anemia, chronic embolism thrombosis, chronic leukemia, immune deficiency disease, lymphoma, multiple myeloma, neutropenia and purpura and thrombocytopenia among the conditions Dr. Heyman treats.

CMS data shows 946 Medicare services from Dr. Heyman across 9 procedure codes in 2024, for 263 Medicare patients. Medicare paid $58,659 for them.

CMS counts 263 Medicare patients who saw Dr. Heyman in 2024. The largest group is 75 to 84, with 106 patients. 73% of them have high cholesterol, and 70% have high blood pressure. 27% are also on Medicaid. Their average risk score is 2.17, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Heyman's median patient age at 69, with 49% women.

In 2024, Dr. Heyman wrote 1,384 Medicare Part D claims for 94 patients. 71% of them were for generic drugs. CMS names the drug for 1,179 of them, across 29 drugs with 11 or more claims each, at $4,134,100 in total drug cost.

Dr. Heyman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Heyman as offering telehealth.

Dmand AI links 22 papers to Dr. Heyman, published from 2013 to 2025. 2016 was the busiest year, with 2. The most frequent topics are Tumor Microenvironment. Dr. Heyman has published most often in Cancers (Basel). Dr. Heyman's most frequent co-authors are Michael Youngjun Choi, MD, Anne Wood Beaven, MD and Nisha Hariharan, MD.

CMS Open Payments shows 11 general payments to Dr. Heyman from 6 drug and device companies from 2024 to 2025. Consulting fees make up the largest share, 57% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $5,801.

Dr. Heyman graduated from UVA School of Medicine in 2011.

Dr. Heyman is in network with 13 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.